In a major development in the field of healthcare, United Kingdom (UK)-based conglomerate SRAM & MRAM Group has announced a joint venture with CELLAAX, a leading Malaysian cellular therapy biopharmaceutical company. The strategic collaboration is poised to revolutionise stem cell treatment not only in India but also across multiple regions worldwide.

By combining their respective expertise and resources, the partnership aims to spearhead advancements in the field of regenerative medicine. Cutting-edge technologies and exceptional medical know-how will be harnessed to deliver innovative solutions for patients grappling with diverse diseases and disorders in the region.

This alliance marks a significant step forward in the quest to improve healthcare outcomes and enhance the quality of life for countless individuals.  

Through this strategic partnership, the fusion of expertise and resources will undoubtedly catalyse groundbreaking strides in the field of cellular therapy. As the two entities synergise their strengths, the potential for novel treatments and transformative healthcare solutions becomes all the more promising.  

Under the agreement, SRAM & MRAM Group has taken exclusive rights for the distribution of CELLAAX’s stem cell treatment in India, as well as in other countries. The collaboration is expected to provide a significant boost to stem cell research and treatment in India and other regions, where access to such treatments is limited or non-existent. This venture/collaboration is expected to fuel the growth of the partnership and accelerate the development of new stem cell treatments and therapies. 

The Group's venture into India will kickstart with Siddhanta Hospital in Bhopal. The institution boasts an Intensive Critical Care Unit that adheres to international standards, further underlining its commitment to providing exceptional patient care.